Newsletter

Argenx Reports Positive Phase 3 Clinical Trial Results

On May 26, argenx (ARGX) reported positive Phase 3 clinical trial results from the ADAPT trial of efgartigimod. The ADAPT trial evaluates improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score for acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients. Respondents in the trial saw an improvement of at least two points […]

Read more...

Ultragenyx Reports Positive Initial Data on DTX401 Clinical Trial

On May 15, Ultragenyx Pharmaceutical Inc. (RARE) presented positive initial data from all three cohorts in its DTX401 clinical trial. DTX401 is an adeno-associated virus-based gene therapy. It is undergoing clinical trials for the treatment of glycogen storage disease type 1a (GSD1a). All patients demonstrated significant cornstarch reductions over time and increases in time to […]

Read more...

April 2020 Scorecard

The April 2020 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide FacebookGoogle+Twitter

Read more...

FDA Grants Accelerated Approval to Immunomedics for Trodelvy in Breast Cancer Patients

On April 22, Immunomedics, Inc. (IMMU) announced that they received accelerated FDA approval of Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC). The treatment is specifically for patents who have received at least two prior therapies for metastatic disease. This is a particularly aggressive form of cancer for […]

Read more...

GenMark Diagnostics Provides Preliminary Financials for First Quarter and Increases Guidance for 2020

On April 7, GenMark Diagnostics, Inc. (GNMK) provided preliminary financial results for the quarter ending March 31, 2020. During the first quarter, GenMark received FDA emergency use authorization for its ePlex SARS-CoV-2 Test. Total revenue estimates for the first quarter are $38.7 million, which is an 80% increase over the first quarter of 2019. GenMark […]

Read more...